Recent studies have begun to elucidate CD155’s involvement in epithelial-mesenchymal transition (EMT) and cytoskeletal reorganization, further supporting its therapeutic relevance.17,18 Furthermore, targeting CD155 may offer a strategy to impair both immune evasion and the intrinsic invasiveness of tumor cells, making it a uniquely advantageous molecular entry point. This evidence concerns the gene PVR and neoplasm.